 Advertisement | ||||||||
 | ||||||||
|
||||||||
 |
 |
 |
 |
 |
 |
 |
||
|
From the Department of Epidemiology and Biostatistics, McGill University, and the Division of Clinical Epidemiology, Montreal General Hospital, Montréal, Que. (Zhou, Rahme, Abrahamowicz, Pilote); the Institute for Clinical Evaluative Science, Toronto, Ont. (Tu, Austin); the Division of Cardiology, University of British Columbia, and the Centre for Health Evaluation and Outcome Sciences, Vancouver, BC (Humphries); and the Sir Mortimer B. Davis Jewish General Hospital, Montréal, Que. (Eisenberg).
Correspondence to: Dr. Louise Pilote, Division of Clinical Epidemiology, Rm. L10-421, Montreal General Hospital, 1650 Cedar Ave., Montréal QC H3G 1A4; fax 514 934-8293; louise.pilote{at}mcgill.ca
Background: Clinical trials have shown the benefits of statins after acute myocardial infarction (AMI). However, it is unclear whether different statins exert a similar effect in reducing the incidence of recurrent AMI and death when used in clinical practice.
Methods: We conducted a retrospective cohort study (1997–2002) to compare 5 statins using data from medical administrative databases in 3 provinces (Quebec, Ontario and British Columbia). We included patients aged 65 years and over who were discharged alive after their first AMI-related hospital stay and who began statin treatment within 90 days after discharge. The primary end point was the combined outcome of recurrent AMI or death from any cause. The secondary end point was death from any cause. Adjusted hazard ratios (HRs) for each statin compared with atorvastatin as the reference drug were estimated using Cox proportional hazards regression analysis.
Results: A total of 18 637 patients were prescribed atorvastatin (n = 6420), pravastatin (n = 4480), simvastatin (n = 5518), lovastatin (n = 1736) or fluvastatin (n = 483). Users of different statins showed similar baseline characteristics and patterns of statin use. The adjusted HRs (and 95% confidence intervals) for the combined outcome of AMI or death showed that each statin had similar effects when compared with atorvastatin: pravastatin 1.00 (0.90–1.11), simvastatin 1.01 (0.91–1.12), lovastatin 1.09 (0.95–1.24) and fluvastatin 1.01 (0.80–1.27). The results did not change when death alone was the end point, nor did they change after adjustment for initial daily dose or after censoring of patients who switched or stopped the initial statin treatment.
Interpretation: Our results suggest that, under current usage, statins are equally effective for secocondary prevention in elderly patients after AMI.
Related Article
This article has been cited by other articles:
|
|
 |
|
  O. K. Bhattacharyya MD PhD, B. R. Shah MD PhD, and G. L. Booth MD MSc Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines Can. Med. Assoc. J., October 21, 2008; 179(9): 920 - 926. [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Daskalopoulou, J. A.C. Delaney, K. B. Filion, J. M. Brophy, N. E. Mayo, and S. Suissa Discontinuation of statin therapy following an acute myocardial infarction: a population-based study Eur. Heart J., September 1, 2008; 29(17): 2083 - 2091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Salanti, J. P. Higgins, A. Ades, and J. P. Ioannidis Evaluation of networks of randomized trials Statistical Methods in Medical Research, June 1, 2008; 17(3): 279 - 301. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Afilalo, G. Duque, R. Steele, J. W. Jukema, A. J.M. de Craen, and M. J. Eisenberg Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 37 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K Choudhry, R. Levin, and W. C Winkelmayer Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice Heart, August 1, 2007; 93(8): 945 - 951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Karp, S.-F. Chen, and L. Pilote Sex differences in the effectiveness of statins after myocardial infarction Can. Med. Assoc. J., January 30, 2007; 176(3): 333 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C Austin, M. M Mamdani, and D. N Juurlink How Many "Me-Too" Drugs Are Enough? The Case of Physician Preferences for Specific Statins Ann. Pharmacother., June 1, 2006; 40(6): 1047 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Prigent An evaluation of class effect. Can. Med. Assoc. J., February 14, 2006; 174(4): 502 - 502. [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhou, E. Rahme, and L. Pilote An evaluation of class effect. Can. Med. Assoc. J., February 14, 2006; 174(4): 502 - 502. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kennedy, H. Quan, A. M. Buchan, W. A. Ghali, and T. E. Feasby Statins Are Associated With Better Outcomes After Carotid Endarterectomy in Symptomatic Patients Stroke, October 1, 2005; 36(10): 2072 - 2076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wright Are the benefits of statins a class effect? Can. Med. Assoc. J., April 26, 2005; 172(9): 1195 - 1196. [Full Text] [PDF]
|
|
Read all eLetters
| HOME | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | HELP | SEARCH |
|
|||||
|
Copyright 1995-2005, Canadian Medical Association. All rights reserved. ISSN 1488-2329
(e) 0820-3946 (p)
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association. |
|||||
